Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea
· Delayed Price · Currency is KRW 6,760.00
-40.00 (-0.59%)
Last updated: Apr 29, 2026, 2:19 PM KST
Kyongbo Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 182.29 | 4,639 | 2,974 | 610.59 | -7,495 | Upgrade
|
| Depreciation & Amortization | 13,204 | 12,408 | 11,699 | 11,936 | 12,757 | Upgrade
|
| Loss (Gain) From Sale of Assets | 149.12 | 6.29 | 11.08 | -121.98 | -58.68 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | -43.11 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -12.02 | 130 | 228.13 | 134.66 | 3,836 | Upgrade
|
| Loss (Gain) on Equity Investments | -4,151 | 1,376 | 376.33 | 463.72 | 85.58 | Upgrade
|
| Provision & Write-off of Bad Debts | 56.89 | 397.06 | 186.82 | -893.1 | - | Upgrade
|
| Other Operating Activities | 888.68 | -374.74 | 3,093 | 950.55 | -2,099 | Upgrade
|
| Change in Accounts Receivable | -11,854 | 4,466 | -6,243 | -3,152 | 4,700 | Upgrade
|
| Change in Inventory | 9,861 | -17,810 | -16,280 | -274.29 | 3,933 | Upgrade
|
| Change in Accounts Payable | -60.28 | -8,079 | 8,256 | -1,562 | 2,097 | Upgrade
|
| Change in Other Net Operating Assets | -809.41 | 2,991 | 586.16 | 2,034 | 212.73 | Upgrade
|
| Operating Cash Flow | 7,456 | 149.12 | 4,844 | 10,127 | 17,968 | Upgrade
|
| Operating Cash Flow Growth | 4899.82% | -96.92% | -52.16% | -43.64% | -13.60% | Upgrade
|
| Capital Expenditures | -41,538 | -12,697 | -9,693 | -12,874 | -17,506 | Upgrade
|
| Sale of Property, Plant & Equipment | 27.1 | 17.86 | 21.88 | 272.27 | 101.9 | Upgrade
|
| Sale (Purchase) of Intangibles | -55.92 | -478.46 | -949.21 | -310.13 | -817.33 | Upgrade
|
| Investment in Securities | 5,895 | -749.48 | -3,183 | -1,680 | 2,123 | Upgrade
|
| Other Investing Activities | -2,308 | -726 | -464.64 | -285.81 | -74.59 | Upgrade
|
| Investing Cash Flow | -37,981 | -14,633 | -14,268 | -14,877 | -16,174 | Upgrade
|
| Short-Term Debt Issued | 233,973 | 184,082 | 144,266 | 148,765 | 145,265 | Upgrade
|
| Long-Term Debt Issued | 24,000 | - | - | - | - | Upgrade
|
| Total Debt Issued | 257,973 | 184,082 | 144,266 | 148,765 | 145,265 | Upgrade
|
| Short-Term Debt Repaid | -221,921 | -167,941 | -135,050 | -140,098 | -151,259 | Upgrade
|
| Long-Term Debt Repaid | -1,096 | -1,078 | -861.44 | -882.17 | -837.12 | Upgrade
|
| Total Debt Repaid | -223,017 | -169,019 | -135,911 | -140,981 | -152,097 | Upgrade
|
| Net Debt Issued (Repaid) | 34,956 | 15,063 | 8,354 | 7,784 | -6,831 | Upgrade
|
| Dividends Paid | -1,195 | -1,195 | -1,195 | -1,195 | -2,391 | Upgrade
|
| Other Financing Activities | -0 | - | -0 | -0 | - | Upgrade
|
| Financing Cash Flow | 33,761 | 13,868 | 7,159 | 6,589 | -9,222 | Upgrade
|
| Foreign Exchange Rate Adjustments | -134.81 | 266.24 | 392.98 | 219.91 | 278.45 | Upgrade
|
| Net Cash Flow | 3,101 | -349.31 | -1,871 | 2,058 | -7,149 | Upgrade
|
| Free Cash Flow | -34,083 | -12,547 | -4,849 | -2,747 | 461.73 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -94.72% | Upgrade
|
| Free Cash Flow Margin | -12.90% | -5.26% | -2.24% | -1.40% | 0.27% | Upgrade
|
| Free Cash Flow Per Share | -1495.72 | -524.69 | -202.82 | -116.97 | 19.34 | Upgrade
|
| Cash Interest Paid | 4,522 | 4,312 | 3,407 | 1,551 | 1,190 | Upgrade
|
| Cash Income Tax Paid | 469.95 | 208.49 | 200.92 | 5.29 | 976.16 | Upgrade
|
| Levered Free Cash Flow | -31,501 | -13,901 | -6,351 | -5,058 | 904.92 | Upgrade
|
| Unlevered Free Cash Flow | -28,819 | -11,220 | -4,225 | -4,014 | 1,640 | Upgrade
|
| Change in Working Capital | -2,863 | -18,433 | -13,681 | -2,953 | 10,942 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.